** Drug and devices maker Johnson & Johnson JNJ.N falls 2.7% to $161.41 premarket
** U.S. bankruptcy judge rejects JNJ's $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer
** This is the third time co's bankruptcy strategy has failed in court
** J&J has been attempting to resolve the lawsuits through subsidiary company's bankruptcy, after two previous bankruptcy attempts failed in other courts
** Leerink Partners says since the bankruptcy plan was dismissed, claimants can continue to proceed with individual trials against co
** Stock gains 14.7% this year, as of last close
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。